Palisade Bio, Inc. (PALI) stock
PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.01−0.02 (-1.94%)
Close on Nov 17, 2026Market cap $176.01MP/E –Yield –
Palisade Bio r&d expenses
Research and development expenses are spending on new products and technology.
Palisade Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $19.57M, up 5.1% year over year. For fiscal 2025 it was $10.19M, down 36.3% from the year before. Over ten years it grew -2.1% a year on average. The highest annual figure on record is $16.00M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.19M | -36.3% |
| FY2024 | Dec 31, 2024 | $16.00M | +132.1% |
| FY2023 | Dec 31, 2023 | $6.89M | +5.3% |
| FY2022 | Dec 31, 2022 | $6.55M | +169.4% |
| FY2021 | Dec 31, 2021 | $2.43M | -21.6% |
| FY2020 | Dec 31, 2020 | $3.10M | -23.7% |
| FY2019 | Dec 31, 2019 | $4.06M | +2.6% |
| FY2018 | Dec 31, 2018 | $3.96M | -51.1% |
| FY2017 | Dec 31, 2017 | $8.10M | -38.5% |
| FY2016 | Dec 31, 2016 | $13.16M | +4.1% |
| FY2015 | Dec 31, 2015 | $12.64M | +51.1% |
| FY2014 | Dec 31, 2014 | $8.36M | +14.8% |
| FY2013 | Dec 31, 2013 | $7.29M | +19.3% |
| FY2012 | Dec 31, 2012 | $6.11M | -17.0% |
| FY2011 | Dec 31, 2011 | $7.35M | -19.7% |
| FY2010 | Dec 31, 2010 | $9.16M | +71.4% |
| FY2009 | Dec 31, 2009 | $5.35M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.00M | +258.2% |
| Q1 FY2026 | Mar 31, 2026 | $6.00M | +531.6% |
| Q4 FY2025 | Dec 31, 2025 | $6.17M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.39M | -91.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.68M | -36.3% |
| Q1 FY2025 | Mar 31, 2025 | $950.00K | -57.1% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.00M | +660.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.63M | +20.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.21M | +78.4% |
| Q4 FY2023 | Dec 31, 2023 | $362.00K | -84.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.10M | +9.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.18M | +65.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.24M | +29.4% |
| Q4 FY2022 | Dec 31, 2022 | $2.34M | +192.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.93M | +209.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.32M | +319.4% |
| Q1 FY2022 | Mar 31, 2022 | $959.00K | +38.6% |
| Q4 FY2021 | Dec 31, 2021 | $800.00K | +1.9% |
| Q3 FY2021 | Sep 30, 2021 | $624.00K | +51.5% |
| Q2 FY2021 | Jun 30, 2021 | $314.00K | -51.7% |
| Q1 FY2021 | Mar 31, 2021 | $692.00K | -0.7% |
| Q4 FY2020 | Dec 31, 2020 | $785.00K | +2.3% |
| Q3 FY2020 | Sep 30, 2020 | $412.00K | -50.1% |
| Q2 FY2020 | Jun 30, 2020 | $650.00K | -31.9% |
| Q1 FY2020 | Mar 31, 2020 | $696.89K | -54.0% |
| Q4 FY2019 | Dec 31, 2019 | $767.05K | -12.7% |
| Q3 FY2019 | Sep 30, 2019 | $825.49K | -8.0% |
| Q2 FY2019 | Jun 30, 2019 | $954.45K | -5.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.51M | +29.5% |
| Q4 FY2018 | Dec 31, 2018 | $878.87K | -28.3% |
| Q3 FY2018 | Sep 30, 2018 | $897.10K | -35.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.01M | -60.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.17M | -59.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.23M | -69.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.38M | -61.5% |
| Q2 FY2017 | Jun 30, 2017 | $2.59M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.59M | – |
See a number that looks wrong?